Thursday - April 02, 2026

Category Archives: Pharmaceuticals & Biotech

Motor Neuron Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 180+ Key Companies | DelveInsight

DelveInsight’s, “Motor Neuron Disease Pipeline Insight 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Motor Neuron Disease pipeline landscape. It covers the Motor Neuron Disease pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Melanoma Clinical Trial Pipeline Gains Momentum: 150+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Melanoma Pipeline Insights 2026” report provides comprehensive insights about 150+ companies and 170+ pipeline drugs in the Melanoma Pipeline landscape. It covers the Melanoma Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Melanoma pipeline … Continue reading →

Chronic and Acute Pain Treatment Pipeline Shows Strong Momentum as 180+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Chronic and Acute Pain Pipeline Insight, 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Chronic and Acute Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Severe Hypertriglyceridemia Clinical Trial Pipeline Expands as 8+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Severe Hypertriglyceridemia Pipeline Insight, 2026” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Severe Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment … Continue reading →

Non-Hodgkin Lymphoma Treatment Pipeline Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Non-Hodgkin Lymphoma Pipeline Insight, 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Non-Hodgkin Lymphoma pipeline landscape. It covers the Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

ADM Endeavors (OTCQB: ADMQ) Gains Investor Attention as Earnings Ramp and Facility Expansion Drives Growth

ADM Endeavors (OTCQB: ADMQ) is drawing increased investor interest following the release of its 2025 financial results, as improving profitability and major infrastructure expansion position the company for growth in 2026. Shares recently reached an intraday high of $0.033, up … Continue reading →

Radioligand Therapy (RLT) Market to Surpass $10.91 Billion by 2035

Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide Tetraxetan, (Lu-177)- PNT2002, Radium-223 dichloride), Target (PSMA, SSTR, Bone Metastases), Indication (Prostate Cancer, Neuroendocrine Tumors (NETS), SCLC) – Global Forecast to 2035 According to MarketsandMarkets™, the global Radioligand therapy market is projected … Continue reading →

Targeted Protein Degradation Market to Reach $9.85 Billion by 2035

Targeted Protein Degradation Market by Type [PROTACs (Vepdegestrant, Bavdegalutamide), SERDs (Elacestrant), Molecular Glues (Mezigdomide), LDD, LYTAC/ATAC], Indication (Oncology, Inflammatory), Formulation (Oral), End User – Global Forecast to 2035 According to MarketsandMarkets™, the report ” Targeted Protein Degradation Market by Type … Continue reading →